Cubist Systematic Strategies LLC Boosts Stake in ADMA Biologics Inc $ADMA

Key Points

• Cubist Systematic Strategies LLC raised its stake in ADMA Biologics by 26.0%, owning approximately 483,797 shares valued at $9.6 million as of its latest SEC filing.
• ADMA Biologics reported earnings per share of $0.15 for the quarter, exceeding analysts' expectations, with a revenue increase of 13.8% year-over-year.
• Several hedge funds recently invested in ADMA, with institutional ownership at 75.68%, signaling strong interest in the biotechnology company's stock.

Cubist Systematic Strategies LLC boosted its position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 26.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 483,797 shares of the biotechnology company's stock after buying an additional 99,721 shares during the period. Cubist Systematic Strategies LLC owned 0.20% of ADMA Biologics worth $9,599,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of ADMA. Nuveen LLC purchased a new stake in ADMA Biologics during the 1st quarter worth approximately $93,543,000. Driehaus Capital Management LLC increased its stake in ADMA Biologics by 114.9% during the 1st quarter. Driehaus Capital Management LLC now owns 2,946,570 shares of the biotechnology company's stock worth $58,460,000 after buying an additional 1,575,363 shares in the last quarter. Invesco Ltd. increased its stake in ADMA Biologics by 13.9% during the 1st quarter. Invesco Ltd. now owns 12,866,904 shares of the biotechnology company's stock worth $255,279,000 after buying an additional 1,570,649 shares in the last quarter. Russell Investments Group Ltd. increased its stake in ADMA Biologics by 152.7% during the 1st quarter. Russell Investments Group Ltd. now owns 1,632,675 shares of the biotechnology company's stock worth $32,392,000 after buying an additional 986,666 shares in the last quarter. Finally, MetLife Investment Management LLC increased its stake in ADMA Biologics by 714.1% during the 1st quarter. MetLife Investment Management LLC now owns 1,108,911 shares of the biotechnology company's stock worth $22,001,000 after buying an additional 972,699 shares in the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Jerrold B. Grossman sold 10,000 shares of the stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $21.31, for a total value of $213,100.00. Following the completion of the sale, the director owned 478,194 shares of the company's stock, valued at $10,190,314.14. This represents a 2.05% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Steve Elms sold 194,749 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the completion of the sale, the director directly owned 87,330 shares of the company's stock, valued at approximately $1,767,559.20. This trade represents a 69.04% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 455,621 shares of company stock valued at $9,461,633 in the last 90 days. Company insiders own 3.50% of the company's stock.

ADMA Biologics Price Performance

ADMA stock traded down $0.04 during mid-day trading on Friday, reaching $16.87. The company's stock had a trading volume of 2,792,474 shares, compared to its average volume of 3,013,706. The stock has a market cap of $4.03 billion, a PE ratio of 19.62 and a beta of 0.54. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21. ADMA Biologics Inc has a fifty-two week low of $13.50 and a fifty-two week high of $25.67. The company's 50 day moving average is $17.67 and its two-hundred day moving average is $18.93.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.14 by $0.01. The company had revenue of $121.98 million during the quarter, compared to the consensus estimate of $121.77 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. ADMA Biologics's quarterly revenue was up 13.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.13 EPS. Equities research analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen downgraded shares of ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. One investment analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus target price of $27.67.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.